Pharmaceutical composition containing botulinum neurotoxin preparation not transported by axon and use thereof

摘要

In order to provide a botulinum toxin preparation having no side effects at a non-administration site, a molecular weight of 150 kDa derived from a botulinum bacterium that does not produce HA protein, and does not exhibit side effects associated with axonal transport at sites other than the administration site A pharmaceutical composition containing a neurotoxin as a main component is used. Since the botulinum neurotoxin is not transported to the non-administration site via the nerve axon as compared with the A1-type botulinum-derived neurotoxin, the botulinum neurotoxin can be administered in a large amount from 15 U to 25 U or less per kg of body weight.